Fluticasone Propionate and Salmeterol Articles

Great expectations for GlaxoSmithKline R&D newsflow

13 December 2012

Forest launches COPD product Tudorza in USA

12 December 2012

Asthma preventive drugs market led by GlaxoSmithKline's Advair

26 November 2012

New LABA/LAMA drugs set to fracture COPD market

10 October 2012

Relovair COPD and asthma filings on track despite more mixed trial results

26 March 2012

EU approval for GlaxoSmithKline and Human Genome’s Benlysta; Slowing Advair sales in USA

15 July 2011

Spiriva viewed as most effective drug for COPD by US pulmonologists

21 March 2011

Increased use of Spiriva will be driven by greater first-line maintenance use

8 December 2010

Vectura gets $9.5 million payoff as Novartis returns US rights to VR315

19 March 2010

USA's NIH updated asthma treatment guidelines welcomed by industry

10 September 2007

Mixed news for high dose Advair from FDA

7 May 2007

GSK's Advair Diskus cuts death risk 17.5%

5 March 2007

IVAX wins Seretide patent case in the UK

29 March 2004

GSK Canadian on-line drug prices rise

7 July 2003

S-P, Novartis link up on asthma product

21 April 2003

GSK boosted by US Advair COPD decision

28 January 2002

GSK launches Advair for asthma in USA; major marketing push planned

18 April 2001

Strong earnings growth for Glaxo Wellcome and SmithKline Beecham

1 November 2000

Stock Commentary Europe

31 August 2000

GW's asthma drug wins US approval

29 August 2000

GW gains first approval for Seretide MDI

20 June 2000

Showing 1-21 of 21 articles

Go to beginningPrevious
  • 1
NextGo to end